Details

Autor(en) / Beteiligte

• Hartner, W C
• Van der Werf, W J
• Lodge, J P
• Gilchrist, B
• De Fazio, S R
• Markees, T G
• Yatko, C
• Monaco, A P
• Gozzo, J J

Titel

Effect of rapamycin on renal allograft survival in canine recipients treated with antilymphocyte serum, donor bone marrow, and cyclosporine

Ist Teil von

• Transplantation, 1995-12, Vol.60 (11), p.1347

Ort / Verlag

United States

Erscheinungsjahr

1995

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Rapamycin (Rapa) monotherapy can promote renal allograft survival in dogs, but it is very toxic. To attempt to augment the effectiveness of Rapa and reduce its toxicity in a tolerance induction protocol, canine renal allograft recipients were treated briefly with antilymphocyte serum (ALS), donor bone marrow cells (BMC), and a limited course of cyclosporine (CsA). Rapa had little effect when CsA-treated recipients were given ALS on days -5 to -1 and BMC on day +1. When combined with CsA given days +13 to +42, ALS on days -5 to +7, and BMC on day +10, Rapa at 0.3 mg/kg on day +8 plus alternate days +15 to +39 significantly increased overall survival and was compatible with long-term survival after immunosuppression (6 grafts, 1 graft > 212 days, 1 graft > 470 days). Rapa appeared to prevent early rejections that can occur during treatment with these ALS/BMC/CsA protocols. Little toxicity of Rapa was observed with any treatment.